Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)

AIM: The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin in individuals with type 1 diabetes who were receiving intensive insulin therapy. The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Mathieu, Chantal, Dandona, Paresh, Birkenfeld, Andreas L, Hansen, Troels Krarup, Iqbal, Nayyar, Xu, John, Repetto, Enrico, Scheerer, Markus Florian, Thoren, Fredrik, Phillip, Moshe
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7693058/
https://ncbi.nlm.nih.gov/pubmed/32691513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados